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Pulmonary capillary hemangiomatosis (PCH) is a rare histological substrate within the spectrum of pulmonary arterial
hypertension that possibly represents an unusual manifestation of pulmonary veno-occlusive disease (PVOD). One of the
histological hallmarks of PCH is the proliferation of pulmonary capillaries in the alveolar septa that infiltrate adjacent structures
such as bronchioles, vessels, and visceral pleura. The hyperplastic process involving the smallest vessels of the pulmonary vascular
bed might reflect uncontrolled angiogenesis, but whether this vascular proliferation is idiopathic or, conversely, a reactive process
remains to be elucidated. Here we discuss the pathogenesis of PCH exemplified by the first reported case of a young patient with
repaired scimitar syndrome that developed unilateral PCH.
1. Background
Pulmonary capillary hemangiomatosis (PCH) and pulmo-
nary veno-occlusive disease (PVOD) are rare types of histo-
pathological substrates within the spectrum of pulmonary
arterial hypertension (PAH). PCH is characterized by exten-
sive proliferation of pulmonary capillaries. The etiology of
these alterations is unclear. PCH has been reported to occur
both idiopathically and hereditarily. In addition, PCH might
represent a reactive process due to hypoxia and chronic
congestion. In the context of congenital heart disease, several
mechanisms including impaired pulmonary venous outflow
and reactive circulatory overload might predispose to the
development of PCH. Here we describe the case of a patient
with scimitar syndrome that developed unilateral PCH fol-
lowing surgical repair. The findings discussed support the
concept that PCH is a reactive angioproliferative process.
2. Case
We here describe a 28-year-old female patient who was
diagnosed with scimitar syndrome a few days after birth.
Scimitar syndrome is a very rare anomaly described to occur
in about two of 100,000 births, of which females are affected
in a twofold predominance. This syndrome is defined by
the presence of a scimitar vein that provides an abnormal
venous drainage of the right lung into the inferior vena
cava. In addition, several other cardiopulmonary anomalies
have been described in association with a scimitar vein
(reviewed in [1]) including but not limited to hypoplasia of
the right lung with consecutive dextroposition of the right
heart, pulmonary sequestration, perimembranous ventric-
ular septal defect, and a persistent ductus arteriosus. All
these abnormal findings were present in the case described
here.
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Figure 1: Schematic representation of preoperative situation (a) and after surgery (b). Surgical repair of the scimitar anomaly included
redirection of the lung veins via patch into the left atrium, closure of the ventricular septal defect, and ligature of the ductus arteriosus.
At the age of five months, the girl underwent surgical
repair to redirect the anomalous lung veins via patch into
the left atrium, closure of the ventricular septal defect, and
ligature of the ductus arteriosus. The pre- and postoperative
situations are illustrated in Figure 1.Thepostoperative cardiac
catheterization on the day of the operation showed complete
obstruction of the right-sided pulmonary venous return and
missing anterograde perfusion of the right lung. Due to the
complex anatomical situation no further surgical interven-
tions were performed and the patient remained stable with
slightly impaired functional capacity for over 20 years.
At the age of 28, hemodynamic assessment by right
heart catheterization confirmed complete occlusion of the
right pulmonary artery and elevated pulmonary pressure
(mean pulmonary arterial pressure (mPAP) of 29mmHg
with normal wedge pressure (PAWP) of 14mmHg). Long-
term oxygen therapy and PH-specific treatment with an
endothelin-receptor antagonist (bosentan) were established.
The course during the following years was characterized
by frequent pulmonary infections but the clinical status
remained stable under treatment with bosentan, diuretics,
and oral anticoagulation. At the age of 34, a new episode
of severe pulmonary infection with subsequent respiratory
failure, septic shock, andmultiorgan failure occurred.Despite
maximal therapeutic efforts, the patient deteriorated further
and died one day after deescalation of treatment to a palliative
concept.
At autopsy, complete occlusion of the redirected right
pulmonary veins and hypoplasia of the right lungwere found.
The lungs had dense consolidation suggesting diffuse alveolar
damage as a consequence of pulmonary infection and acute
respiratory distress syndrome. Massive dilatation and hyper-
trophy of the right ventricle was found (“cor pulmonale”)
indicating severe pulmonary hypertension and right heart
failure. Microscopic analysis (Figure 2) showed pulmonary
veno-occlusive disease with prominent pulmonary capillary
hemangiomatosis of the left lung. In particular, thickening
of the alveolar septa due to capillary proliferation and
congestion andmassive iron deposition in the alveolar spaces
secondary to venous obstruction were found (Figure 2(a)).
Moreover, arterialization and intimal fibrosis of venules
in the interlobular septa with subtotal luminal occlusion
were described (Figure 2(b)). Conversely, the right lung was
characterized by a normal alveolar architecture (Figure 2(c)).
Right-sided pulmonary arteries showed alterations probably
due to pressure overload with intimal proliferation and
hypertrophy of the medial layer (Figure 2(d)) but no signs of
PCH or PVOD, indicating a reactive, unilateral process of the
left lung.
3. Discussion
3.1. Pulmonary Hypertension in Grown-Up Congenital Heart
Disease (GUCH). Pulmonary hypertension (PH) is hemo-
dynamically defined by an increase of the mean pulmonary
arterial pressure (mPAP) ≥25mmHg and, according to the
pulmonary arterial wedge pressure (PAWP), can further be
distinguished in pre- and postcapillary PH [2]. PH is an
umbrella term [3] and subsumes many different clinical
entities, which are classified in five distinct groups shown as
follows.
Simplified Classification of Pulmonary
Hypertension (Modified from [4])
(1) Pulmonary arterial hypertension (PAH):
(1.1) Idiopathic.
(1.2) Heritable.
(1.3) Drug and toxin-induced.
(1.4) Associated with connective tissue disease, HIV
infection, portal hypertension, congenital heart
diseases, and schistosomiasis.
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Figure 2: Histological pictures from the left lung (a) showing thickening of the alveolar septa due to capillary proliferation and congestion.
In addition, massive iron deposition in the alveolar spaces secondary to venous obstruction is found. The Elastic van Gieson (EvG) staining
(b) highlights arterialization and intimal fibrosis of venules in the interlobular septa with subtotal luminal occlusion. In contrast to the left
lung, the right lung is characterized by a normal alveolar architecture with only minimal congestion (c). The EvG staining (d) shows intimal
proliferation and media hyperplasia possibly related to pressure overload of the right lung but no signs of PCH or PVOD.
(1
󸀠
) Pulmonary veno-occlusive disease (PVOD) and pul-
monary capillary hemangiomatosis (PCH).
(1
󸀠󸀠
) Persistent pulmonary hypertension of the newborn
(PPHN).
(2) Pulmonary hypertension due to left heart disease.
(3) Pulmonary hypertension due to lung disease and/or
hypoxia.
(4) Chronic thromboembolic hypertension (CTEPH).
(5) Pulmonary hypertension with unclear multifactorial
mechanisms.
Of note, PH related to left-sided heart disease is classified as
group 2, whereas precapillary PH developing in patients with
grown-up congenital heart disease (GUCH) is classified as
group 1 (PAH) [4].
Pathogenic mechanisms and epidemiology of PH in the
cohort of GUCH patient are ill-defined and are affected by
type of the defect and type and timing of surgical repair. The
association between scimitar syndrome and PH, at least in
the preoperative setting, is well known [5–7].Themainstay of
therapy for scimitar syndrome is surgical repair, as performed
in the case of our patient, which improves outcome. However,
these patients are not cured by surgery and long-term
complications including obstruction of redirected pulmonary
veins as observed in the patient described here are not
uncommon [8]. These patients may consecutively develop
postcapillary PH. The role of PH-target therapies in this
setting is of unclear benefit. Of interest, our patient developed
complete occlusion of the right pulmonary artery, and ele-
vated pulmonary pressure was measured in the contralateral
(left) pulmonary artery, with normal wedge pressure. These
observations implicate other pathogenic mechanisms for PH
in our patient.
As such, the necroptic findings of combined PCH and
pulmonary veno-occlusive disease (PVOD) in the left lung
might provide a plausible explanation for this unique constel-
lation.
3.2. Pulmonary Capillary Hemangiomatosis and Pulmonary
Veno-Occlusive Disease. Pulmonary capillary hemangioma-
tosis (PCH) and pulmonary veno-occlusive disease (PVOD)
represent rare, different types of histological substrates within
the spectrum of PH group 1 (PAH) that involve the capillaries
and the venules, respectively [9].
PCH is characterized by abnormal proliferation of capil-
lary vessels in the pulmonary interstitium, leading to thick-
ening of the alveolar septa. These capillaries are typically
located around the bronchovascular bundles and frequently
invade small pulmonary vessels. Vascular proliferation may
lead to arterial or venous occlusion and nodular lesions
(Figure 2). Unspecific histological hallmarks include intimal
thickening and medial hypertrophy [10]. The etiology of
PCH is unknown. While the onset of PCH appears to
occur sporadically, two familial cases have been reported
that suggest a genetic predisposition [11]. It is assumed that
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chronic congestion and hypoxiamight play an important role
in the emergence of PCH [12, 13], since angiogenesis is a
commonly observed response to these triggers. In addition,
inflammation and increased levels of local growth factors
might be involved.
PVOD frequently appears together with PCH and is char-
acterized by fibrous intimal thickening resulting in obstruc-
tion of the small pulmonary venules [14, 15]. Whether PCH
and PVOD represent distinct entities or different phenotyp-
ical expression of the same condition with arteriocapillary
or venous predomination is unclear. However, cooccurrence,
as in our case here, is evident [16]. Of note, it is estimated
that PCH/PVOD is found in up to 10% of patients that were
primary thought to have idiopathic PAH [17].
Identification of PCH/PVOD is of major importance
since treatment with PH-target vasodilators might be dev-
astating and result in the development of pulmonary edema
[18]. Anecdotal reports have described improvement of
PCH/PVOD under treatment with Interferon-alpha-2a [19],
but the results are not satisfying and prognosis is poor. The
only curative therapy in these cases is lung transplantation
[20].
While the clinical classification of PH recognizes PCH
as a distinct entity [4], histological studies have provided
evidence that PVOD and PCH represent the extreme ends
of one disease spectrum. In addition, there is a growing
body of evidence suggesting that PCH should be regarded
as a reactive rather than a neoplastic angioproliferative
mechanism [16]. For proliferating capillaries in the context
or as a consequence of PVOD the term “secondary PCH” was
presented and, conversely, “primary PCH” should be reserved
for the rare idiopathic cases of PCH [16]. In congenital
heart disease, however, several conditions such as capillary
congestion due to impaired pulmonary venous outflow and
reactive circulatory overload predispose for the development
of PCH.Consistentwith this hypothesis, two cases of children
with PH in the context of congenital left-to-right cardiac
shunts have been described in which lung biopsy showed
the typical patterns of PCH [21]. Moreover, in one of these
patients a congenital stenosis of the central right pulmonary
arterial branch was identified. This patient developed PCH
in the contralateral lung, indicating hypercirculation and
volume overload as triggering factors.
The occurrence of PCH in one lung only following
operative repair of scimitar syndrome complicated by uni-
lateral pulmonary artery occlusion supports the concept that
PCH is a reactive rather than a neoplastic angioproliferative
process. In this context vascular shear stress induced by
hypercirculation might provide a plausible explanation for
the unilateral manifestation of PCH.
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